research feed

Every NR4A2 paper, in plain English

PubMed and the Europe PMC preprint servers are queried daily for NR4A2 and NURR1, back to the earliest records. Each abstract is summarised locally by Qwen3.6 35B and tagged by relevance to a parent of an NR4A2 child. Source links go straight to the paper.

subscribe (Atom feed) · high and medium relevance only

registered clinical trials

Every ClinicalTrials.gov study whose record mentions NR4A2 or NURR1. Most use NURR1 as a Parkinson's biomarker rather than testing anything for this syndrome, so read the conditions line. Studies still open come first. Last checked 2026-09-13.

completed or inactive (4) ›
medium2020-11-01 · Military Medical Research

Direct conversion of human fibroblasts into dopaminergic neuron-like cells using small molecules and protein factors.

Qin H, Zhao AD, Sun ML, Ma K, Fu XB

Researchers successfully converted human skin cells into dopamine-producing neuron-like cells using a chemical cocktail of small molecules and proteins. This method avoids genetic manipulation, potentially reducing safety risks for future cell replacement therapies in neurodegenerative diseases like Parkinson's.

  • Human fibroblasts convert to dopamine neuron-like cells with 95% efficiency using chemicals and proteins.
  • The process skips the neural stem cell stage, reducing potential tumorigenic risks.
  • Induced cells express key dopamine markers including NURR1 (NR4A2) and fire electrical signals.
  • This offers a safer alternative to genetic modification for generating therapeutic neurons.
medium2020-10-21 · Parkinsonism & related disorders

Parkinsonism in children: Clinical classification and etiological spectrum.

Leuzzi V, Nardecchia F, Pons R, Galosi S

This paper classifies childhood-onset parkinsonism into distinct clinical categories based on age, symptoms, and genetic causes. It identifies NR4A2 mutations as a specific genetic cause of parkinsonism that presents within the broader context of neurodevelopmental disorders.

  • Childhood parkinsonism is rare and primarily driven by genetic alterations rather than adult-onset disease mechanisms.
  • The authors propose a classification system based on age at onset, clinical features, and underlying etiology.
  • NR4A2 mutations cause parkinsonism that emerges alongside generalized neurodevelopmental derangements.
  • Other identified genetic causes include MECP2, SCN1A, and RAB39B variants.
medium2020-08-14 · Molecular genetics & genomic medicine

Analysis of rare variants of autosomal-dominant genes in a Chinese population with sporadic Parkinson's disease.

Zheng R, Jin CY, Chen Y, Ruan Y, Gao T, Lin ZH, Dong JX, Yan YP, Tian J, Pu JL, Zhang BR

This study screens the NR4A2 gene in humans with sporadic Parkinson's disease to identify rare genetic variants. It finds that while NR4A2 variants are present, they do not show a statistically significant association with the disease in this specific Chinese cohort.

  • Researchers sequenced 12 autosomal-dominant Parkinson's genes in 391 patients.
  • NR4A2 was one of the genes analyzed for rare variants.
  • LRRK2 variants showed a strong link to sporadic Parkinson's disease risk.
  • NR4A2 variants did not reach statistical significance for association with the disease.
  • The study confirms LRRK2's role but offers limited insight into NR4A2's function in this context.
medium2020-05-25 · Nature chemical biology

PGE1 and PGA1 bind to Nurr1 and activate its transcriptional function.

Rajan S, Jang Y, Kim CH, Kim W, Toh HT, Jeon J, Song B, Serra A, Lescar J, Yoo JY, Beldar S, Ye H, Kang C, Liu XW, Feitosa M, Kim Y, Hwang D, Goh G, Lim KL, Park HM, Lee CH, Oh SF, Petsko GA, Yoon HS, Kim KS

Prostaglandins PGE1 and PGA1 bind directly to the NR4A2 protein (Nurr1) and activate its function, leading to neuroprotection in dopaminergic neurons. These compounds improve motor deficits in mouse models of Parkinson's disease by enhancing the expression of genes controlled by NR4A2.

  • PGE1 and PGA1 bind covalently to the NR4A2 protein structure.
  • This binding activates NR4A2 transcriptional function in dopaminergic neurons.
  • The treatment shows neuroprotective effects in Parkinson's disease mouse models.
  • Motor deficits improve when NR4A2 is activated by these prostaglandins.
high2020-05-05 · Genetics in medicine : official journal of the American College of Medical Genetics

De novo variants of NR4A2 are associated with neurodevelopmental disorder and epilepsy.

Singh S, Gupta A, Zech M, Sigafoos AN, Clark KJ, Dincer Y, Wagner M, Humberson JB, Green S, van Gassen K, Brandt T, Schnur RE, Millan F, Si Y, Mall V, Winkelmann J, Gavrilova RH, Klee EW, Engleman K, Safina NP, Slaugh R, Bryant EM, Tan WH, Granadillo J, Misra SN, Schaefer GB, Towner S, Brilstra EH, Koeleman BPC

This study identifies NR4A2 as a confirmed cause of neurodevelopmental disorders and epilepsy in humans, describing the specific clinical features associated with these genetic variants. It provides direct evidence linking de novo mutations in this gene to developmental delay, hypotonia, and seizures in patients.

  • NR4A2 variants cause neurodevelopmental disorder and epilepsy in human patients.
  • Six of nine patients presented with developmental delay and hypotonia.
  • Six of nine patients experienced epilepsy alongside other symptoms.
  • Variants include missense, loss-of-function, and splicing defects.
  • The study confirms NR4A2 is a causative disease gene.
medium2020-05-05 · Experimental neurology

Striatal Nurr1, but not FosB expression links a levodopa-induced dyskinesia phenotype to genotype in Fisher 344 vs. Lewis hemiparkinsonian rats.

Steece-Collier K, Collier TJ, Lipton JW, Stancati JA, Winn ME, Cole-Strauss A, Sellnow R, Conti MM, Mercado NM, Nillni EA, Sortwell CE, Manfredsson FP, Bishop C

This study identifies striatal Nurr1 expression as a key molecular marker distinguishing levodopa-induced dyskinesia susceptibility in rats, challenging the previous assumption that FosB is the primary driver. The findings suggest that genetic differences in Nurr1 regulation may influence how individuals respond to levodopa treatment.

  • Striatal Nurr1 mRNA increases only in rats susceptible to levodopa-induced dyskinesia.
  • FosB expression rises in both susceptible and resistant rat strains, weakening its causal role.
  • The study uses genetically distinct rat strains to model dyskinesia susceptibility differences.
  • Results suggest reevaluating Nurr1's role in regulating movement side effects of levodopa.
lower-relevance papers (34) ›
low2020-11-13 · Biochimica et biophysica acta. Molecular cell research

Complex regulation of orphan nuclear receptor Nur77 (Nr4a1) transcriptional activity by SUMO2 and PIASγ.

Dodat F, Cotnoir-White D, Dianati E, Vallet A, Mader S, Lévesque D

This study details how specific molecular switches (SUMOylation) regulate the activity of Nur77, a protein closely related to NR4A2. It identifies distinct regulatory mechanisms for Nur77 that differ from those controlling Nurr1 (NR4A2). The findings provide basic mechanistic insight into nuclear receptor biology but do not offer direct clinical guidance or treatment options for NR4A2-related syndromes.

  • SUMO2 and PIASγ repress Nur77 transcriptional activity in cell cultures.
  • Specific mutations at lysine sites alter how SUMOylation affects Nur77 function.
  • Nur77 regulation differs significantly from its homolog Nurr1 (NR4A2).
  • The research focuses on molecular mechanisms without clinical or therapeutic implications.
low2020-11-03 · Cell reports

Nr4a1 and Nr4a3 Reporter Mice Are Differentially Sensitive to T Cell Receptor Signal Strength and Duration.

Jennings E, Elliot TAE, Thawait N, Kanabar S, Yam-Puc JC, Ono M, Toellner KM, Wraith DC, Anderson G, Bending D

This study shows that different Nr4a family genes in T cells respond to immune signals in distinct ways, with Nr4a1 being more sensitive to weak or brief signals than Nr4a3. The findings reveal how T cell development and function are shaped by the strength and duration of immune activation, which may influence immune-related disorders.

  • Nr4a1 responds to weaker T cell signals than Nr4a3
  • Nr4a1 is activated during early T cell development
  • T cell signal duration affects immune cell fate
  • NFAT1 controls Nr4a2 and Nr4a3 expression
  • These genes may influence immune system regulation
low2020-11-03 · Cellular & molecular biology letters

The nuclear receptor 4A family members: mediators in human disease and autophagy.

Chen L, Fan F, Wu L, Zhao Y

This review summarizes how NR4A1, NR4A2, and NR4A3 regulate autophagy and contribute to various human diseases. It highlights that understanding these mechanisms may eventually aid in developing new therapies.

  • The paper reviews the roles of three NR4A family members in disease and autophagy.
  • It discusses how NR4A proteins act as gene regulators in signaling pathways.
  • Better understanding of these mechanisms could improve future drug development processes.
  • The content is a broad overview rather than specific clinical guidance for NR4A2 syndrome.
low2020-11-03 · Poultry science

Seasonal differences in the transcriptome profile of the Zhedong white goose (Anser cygnoides) pituitary gland.

Zhao W, Yuan T, Fu Y, Niu D, Chen W, Chen L, Lu L

This study found that gene activity in goose pituitary glands changes with the seasons, especially around key times like spring and summer when breeding starts. Genes linked to reproduction, stress response, and hormone signaling shift in expression, helping explain how geese time their breeding to maximize offspring survival.

  • Pituitary gene activity varies with seasons in geese
  • NR4A2 and other transcription factors change seasonally
  • Hormone receptors and stress genes are involved in breeding timing
  • Oxidative stress and steroid pathways support seasonal reproduction
  • Findings help explain how light cues control breeding cycles
low2020-10-26 · Frontiers in molecular neuroscience

Epinephrine May Contribute to the Persistence of Traumatic Memories in a Post-traumatic Stress Disorder Animal Model.

Martinho R, Oliveira A, Correia G, Marques M, Seixas R, Serrão P, Moreira-Rodrigues M

Epinephrine appears to help maintain traumatic memories in a PTSD mouse model, likely by increasing the activity of the Nr4a2 and Nr4a3 genes in the brain. Removing epinephrine reduced fear behaviors, and giving it back restored those memories, showing a direct role in memory persistence.

  • Epinephrine strengthens traumatic memories in PTSD models
  • Nr4a2 and Nr4a3 genes increase with epinephrine in the hippocampus
  • Mice without epinephrine show less fear and anxiety-like behavior
  • Giving epinephrine back restores fear memories in these mice
  • This suggests epinephrine may block memory extinction in PTSD
low2020-10-24 · Neurobiology of disease

Gene expression in the epileptic (EL) mouse hippocampus.

Lee TS, Li AY, Rapuano A, Mantis J, Eid T, Seyfried TN, de Lanerolle NC

This study analyzes gene expression changes in the hippocampus of a mouse model of epilepsy to understand how glial cells contribute to seizures. It identifies specific molecular pathways involving heat shock proteins and immediate early genes, including NR4A2, that may drive neuronal hyperexcitability.

  • The EL mouse model lacks neuron loss but shows glial activation, isolating neuroglia's role in seizures.
  • NR4A2 expression increases alongside other immediate early genes linked to hippocampal hyperexcitability.
  • Activated microglia may remove inhibitory synapses, reducing neuronal inhibition and favoring seizures.
  • Astrocyte deficiency in glutamine synthetase reduces glutamate clearance, potentially worsening excitability.
low2020-10-16 · DNA and cell biology

Differential Expression of microRNA Profiles and Wnt Signals in Stem Cell-Derived Exosomes During Dopaminergic Neuron Differentiation.

Jin T, Gu J, Xia H, Chen H, Xu X, Li Z, Yue Y, Gui Y

Exosomes from stem cells promote the production of dopamine-producing neurons in mouse models. The study identifies specific microRNAs and Wnt signaling pathways within these exosomes that drive this differentiation process.

  • Exosomes from epiblast-derived stem cells boost dopamine neuron generation in mouse embryonic stem cells.
  • Twenty-six microRNAs change expression during this differentiation, with most increasing significantly.
  • Wnt signaling and extracellular matrix interactions are key pathways involved in the process.
  • Nine dopamine neuron marker genes increase in exosomes as differentiation progresses.
low2020-10-06 · Neuropsychiatric disease and treatment

NR4A2 Exacerbates Cerebral Ischemic Brain Injury via Modulating microRNA-652/Mul1 Pathway.

Liu Q, Dong Q

NR4A2 worsens brain damage after stroke by reducing a protective microRNA, which in turn increases a protein that promotes cell death and cell cycle arrest. This pathway may offer a target for future treatments to protect the brain during stroke.

  • NR4A2 increases brain injury after stroke
  • NR4A2 reduces microRNA-652
  • Lower microRNA-652 raises Mul1 protein
  • Mul1 causes cell death and arrest
  • Blocking this pathway could be protective
low2020-09-12 · Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology

Transgenerational modification of dopaminergic dysfunctions induced by maternal immune activation.

Weber-Stadlbauer U, Richetto J, Zwamborn RAJ, Slieker RC, Meyer U

Maternal immune activation in mice causes opposite dopaminergic effects across generations, with first-generation offspring showing hyperdopaminergia and later generations showing blunted responses. These changes correlate with altered DNA methylation of the Nurr1 gene in sperm and brain tissue.

  • First-generation mouse offspring show increased dopamine sensitivity after maternal immune activation.
  • Second- and third-generation offspring display reduced dopamine responses to stimulants.
  • Nurr1 gene methylation increases in sperm of first-generation and brains of later generations.
  • Epigenetic changes in male germline may drive transgenerational dopaminergic dysfunction.
low2020-09-09 · International journal of molecular sciences

Human Mesenchymal Stromal Cells Unveil an Unexpected Differentiation Potential toward the Dopaminergic Neuronal Lineage.

Gaggi G, Di Credico A, Izzicupo P, Alviano F, Di Mauro M, Di Baldassarre A, Ghinassi B

This study shows that stem cells derived from the placenta can be converted into cells that resemble midbrain dopaminergic neurons in a laboratory dish. The resulting cells express key markers like NURR1 and produce dopamine, demonstrating a potential new source for cell replacement therapies.

  • Placental stem cells differentiate into neuron-like cells expressing dopaminergic markers.
  • The cells express NURR1, PITX3, and other midbrain-specific transcription factors.
  • This offers an alternative to pluripotent stem cells for generating dopamine neurons.
  • The research is preclinical and conducted entirely in cell culture systems.
low2020-08-24 · Archives of oral biology

Global gene expression profile of periodontal ligament cells submitted to mechanical loading: A systematic review.

Spitz A, Christovam IO, Marañón-Vásquez GA, Masterson DF, Adesse D, Maia LC, Bolognese AM

This study looked at how mechanical pressure affects gene activity in cells from the periodontal ligament, finding that genes like NR4A2 are involved in responses to mechanical stress. These findings suggest NR4A2 and other genes may serve as biomarkers for tooth movement during orthodontic treatment.

  • NR4A2 is linked to mechanical stress response in periodontal cells
  • Mechanical loading changes gene activity related to cell growth and tissue remodeling
  • 3D culture models show stronger gene responses than 2D models
  • Findings may help understand orthodontic tooth movement mechanisms
  • More standardized studies are needed for definitive results
low2020-08-21 · Cellular reprogramming

The Extracts of Human Fetal Brain Induce the Differentiation of Human Umbilical Cord Mesenchymal Stem Cells into Dopaminergic Neuron Containing Cells.

Li Y, Yang J, Li M, Zhang X, Du J, Zhao X, Xu Z, Lin J

This study demonstrates that human umbilical cord stem cells can be converted into dopamine-producing neuron-like cells in a laboratory dish using extracts from human fetal brain tissue. The method establishes a potential new cell source for treating neurodegenerative diseases like Parkinson's, though it remains an early-stage experimental finding.

  • Human umbilical cord stem cells differentiate into neuron-like cells when treated with fetal brain extracts.
  • Induced cells express key dopaminergic markers including Nurr1, LMX1B, and dopamine transporter.
  • The technique offers a new in vitro method for generating dopamine-producing cells.
  • Results are preclinical and do not involve human patients or clinical trials.
low2020-08-19 · International journal of molecular sciences

Carbon Fibers as a New Type of Scaffold for Midbrain Organoid Development.

Tejchman A, Znój A, Chlebanowska P, Frączek-Szczypta A, Majka M

Carbon fiber scaffolds improve the survival and differentiation of midbrain dopaminergic neurons in organoid cultures compared to traditional polymer materials. This finding establishes a better in vitro model for studying neurodegenerative diseases like Parkinson's, but it does not provide direct clinical insights or treatments for NR4A2-related syndromes.

  • Carbon fibers support midbrain dopaminergic neuron survival better than PLGA scaffolds.
  • The study uses induced pluripotent stem cells to create organoid models in vitro.
  • PITX3 gene expression correlates with the health of these specific neurons.
  • This work creates a tool for Parkinson's research, not a therapy for NR4A2.
  • No human participants or clinical data are involved in this study.
low2020-08-09 · International journal of molecular sciences

Origin of the Induced Pluripotent Stem Cells Affects Their Differentiation into Dopaminergic Neurons.

Chlebanowska P, Sułkowski M, Skrzypek K, Tejchman A, Muszyńska A, Noroozi R, Majka M

The type of skin or blood cell used to create stem cells changes how well those cells turn into dopamine-producing neurons in lab dishes. This technical detail matters for researchers trying to model diseases like NR4A2 syndrome using patient-specific stem cells, but it does not offer a treatment.

  • Stem cell origin affects gene expression during early neuron development.
  • Blood-derived and skin-derived stem cells behave differently in lab models.
  • This is basic laboratory methodology research with no clinical application.
  • It does not test treatments or analyze human patient outcomes.
low2020-07-29 · Journal of molecular neuroscience : MN

Integrative Analysis of Gene Expression and Regulatory Network Interaction Data Reveals the Protein Kinase C Family of Serine/Threonine Receptors as a Significant Druggable Target for Parkinson's Disease.

Odumpatta R, Arumugam M

This computational study identifies NR4A2 as one of several hub genes in Parkinson's disease networks, alongside Protein Kinase C (PRKACB) and other signaling molecules. The analysis suggests these genes interact with specific transcription factors and microRNAs to influence disease pathways.

  • NR4A2 appears as a hub gene in Parkinson's disease network models.
  • Protein Kinase C (PRKACB) is highlighted as a significant druggable target.
  • The study uses bioinformatics, not human or animal experiments.
  • No clinical data or treatment outcomes for NR4A2-related syndromes are presented.
low2020-07-10 · Movement disorders : official journal of the Movement Disorder Society

CD4+ T-cell Transcription Factors in Idiopathic REM Sleep Behavior Disorder and Parkinson's Disease.

De Francesco E, Terzaghi M, Storelli E, Magistrelli L, Comi C, Legnaro M, Mauri M, Marino F, Versino M, Cosentino M

This study measures immune cell gene expression in Parkinson's disease research and does not provide information on NR4A2-related syndromes or treatments. It finds no direct evidence relevant to the genetic cause or management of your child's condition.

  • The study focuses on Parkinson's disease, not NR4A2-related syndromes.
  • Researchers analyzed immune cells from Parkinson's patients and healthy controls.
  • NR4A2 appears only as one of many measured genes in T-cells.
  • Findings do not inform diagnosis or treatment for NR4A2 variants.
low2020-07-03 · Communications chemistry

The orphan nuclear receptor Nurr1 is responsive to non-steroidal anti-inflammatory drugs.

Willems S, Kilu W, Ni X, Chaikuad A, Knapp S, Heering J, Merk D

This study identifies several non-steroidal anti-inflammatory drugs as inverse agonists that reduce Nurr1 activity, providing new chemical tools to study its mechanism. It demonstrates that Nurr1 can be regulated bidirectionally and recruits different co-regulators depending on whether it is activated or inhibited.

  • NSAIDs act as inverse agonists, reducing Nurr1 transcriptional activity.
  • Nurr1 recruits specific co-regulators in a ligand-dependent manner.
  • Dimerization states distinguish between agonist and inverse agonist effects.
  • Findings offer chemical tools for future drug discovery targeting Nurr1.
low2020-07-01 · Scientific reports

Nurr1 performs its anti-inflammatory function by regulating RasGRP1 expression in neuro-inflammation.

Oh M, Kim SY, Gil JE, Byun JS, Cha DW, Ku B, Lee W, Kim WK, Oh KJ, Lee EW, Bae KH, Lee SC, Han BS

This study identifies RasGRP1 as a new target gene that Nurr1 regulates to control inflammation in immune cells. It shows that Nurr1 binds directly to the RasGRP1 gene to manage inflammatory signaling pathways.

  • Nurr1 directly binds to the RasGRP1 gene intron to regulate its expression.
  • RasGRP1 controls the Ras-Raf-MEK-ERK signaling cascade during inflammation.
  • The research uses BV2 microglial cells and LPS-induced inflammation models.
  • This is a molecular mechanism study with no human or clinical data.
low2020-06-30 · Molecules and cells

Genome-Wide Analysis Identifies NURR1-Controlled Network of New Synapse Formation and Cell Cycle Arrest in Human Neural Stem Cells.

Kim SM, Cho SY, Kim MW, Roh SR, Shin HS, Suh YH, Geum D, Lee MA

This study maps the direct genetic targets of NURR1 in human neural stem cells, revealing that the protein regulates networks controlling synapse formation and cell cycle arrest. It confirms that NURR1 expression correlates with processes essential for midbrain dopaminergic development, such as neuronal migration and stopping cell division.

  • Researchers identified approximately 40 direct target genes controlled by NURR1 in human neural stem cells.
  • NURR1 promotes gene expression linked to new synapse formation and neuronal cell migration.
  • NURR1 negatively correlates with genes driving cell cycle progression and DNA replication.
  • Findings align with known roles of NURR1 in midbrain dopaminergic neurogenesis.
low2020-06-20 · Toxicology letters

Transfer of pathological α-synuclein from neurons to astrocytes via exosomes causes inflammatory responses after METH exposure.

Meng Y, Ding J, Li C, Fan H, He Y, Qiu P

This study shows that methamphetamine exposure causes neurons to release pathological alpha-synuclein via exosomes, which astrocytes absorb and trigger inflammatory responses. The research finds that this process reduces Nurr1 (NR4A2) expression in astrocytes, suggesting a link between drug-induced neurotoxicity and inflammation.

  • Methamphetamine causes neurons to release alpha-synuclein inside exosomes.
  • Astrocytes absorb these exosomes and develop inflammatory responses.
  • Alpha-synuclein accumulation in astrocytes decreases Nurr1 expression.
  • Nurr1 reduction may drive inflammation after methamphetamine exposure.
low2020-06-12 · Journal of clinical medicine

Differential Expression of MicroRNAs in Silent and Functioning Corticotroph Tumors.

García-Martínez A, Fuentes-Fayos AC, Fajardo C, Lamas C, Cámara R, López-Muñoz B, Aranda I, Luque RM, Picó A

Certain microRNAs are more active in silent corticotroph tumors than in functioning ones, suggesting they may help suppress hormone production. These microRNAs could be targets for future treatments to control tumor behavior.

  • miR-200a and miR-103 are higher in silent tumors
  • miR-383 links to TBX19, a key hormone regulator
  • Larger tumors show higher levels of several miRNAs
  • These miRNAs may help explain why some tumors don't produce hormones
  • Targeting these miRNAs could lead to new therapies
low2020-06-03 · Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association

Triphenyltin chloride reduces the development of rat adrenal cortex during puberty.

Li X, Li L, Chen X, Li X, Wang Y, Zhu Q, Gao-Smith F, Ge RS

Triphenyltin exposure reduces adrenal hormone production in rats by blocking cholesterol transport and synthesis, which are critical for hormone development during puberty. This effect is linked to the down-regulation of NR4A2 and other key genes involved in adrenal function.

  • Triphenyltin lowers corticosterone and ACTH levels in pubertal rats
  • NR4A2 and other transcription factors are suppressed by triphenyltin
  • Cholesterol transport and synthesis genes are down-regulated
  • NR4A1, LDLR, and HMGCS1 protein levels decrease
  • Oxidative stress increases, but no cell death occurs
low2020-06-01 · Advances in clinical and experimental medicine : official organ Wroclaw Medical University

Weighted gene co-expression network analysis to investigate the key genes implicated in global brain ischemia/reperfusion injury in rats.

Ma D, Qiao J, Qu Q, He F, Chen W, Yu B

This study identifies NR4A2 as a key gene downregulated in rat brains following global ischemia/reperfusion injury, linking it to brain damage mechanisms rather than developmental function. The research focuses on acute stroke-like injury pathways in rodents and does not address the neurodevelopmental aspects of NR4A2 syndrome.

  • NR4A2 levels decrease in rat hippocampus after global ischemia/reperfusion injury.
  • Study uses rodent models to investigate brain damage from reduced blood flow.
  • No human data, clinical cohorts, or developmental phenotypes are included.
  • Findings relate to acute injury mechanisms, not NR4A2-related neurodevelopmental disorders.
low2020-05-26 · The Journal of neuroscience : the official journal of the Society for Neuroscience

Genetic Architecture and Molecular Neuropathology of Human Cocaine Addiction.

Huggett SB, Stallings MC

This study identifies NR4A2 as one of several genes differentially expressed in the brains of individuals with cocaine use disorder, linking it to dopamine neurotransmission pathways. It does not provide new information about NR4A2-related syndromes or potential treatments for children with this condition.

  • NR4A2 shows altered expression in postmortem brain tissue from adults with cocaine addiction.
  • The research focuses on drug use disorder, not developmental disorders or pediatric phenotypes.
  • No clinical trials, genetic screening of NR4A2 variants, or therapeutic interventions are reported.
  • Findings relate to adult neurobiology of addiction rather than childhood neurodevelopment.
low2020-05-22 · PloS one

Correction: Direct Regulation of Pitx3 Expression by Nurr1 in Culture and in Developing Mouse Midbrain.

Volpicelli F, De Gregorio R, Pulcrano S, Perrone-Capano C, di Porzio U, Bellenchi GC

This study confirms that Nurr1 directly controls the expression of Pitx3, a gene critical for midbrain development, in both cell cultures and developing mice. It corrects previous findings regarding the specific mechanism of this genetic regulation.

  • Nurr1 directly regulates Pitx3 expression in mouse midbrain development.
  • The paper corrects prior errors in understanding this regulatory pathway.
  • Findings are based on cell cultures and animal models, not humans.
  • No clinical data or treatment implications for patients are presented.
low2020-05-22 · BMC medicine

Circulating mRNAs are differentially expressed in pregnancies with severe placental insufficiency and at high risk of stillbirth.

Hannan NJ, Stock O, Spencer R, Whitehead C, David AL, Groom K, Petersen S, Henry A, Said JM, Seeho S, Kane SC, Gordon L, Beard S, Chindera K, Karegodar S, Hiscock R, Pritchard N, Kaitu'u-Lino TJ, Walker SP, Tong S

This study identifies NR4A2 mRNA in maternal blood as a biomarker for severe placental insufficiency and fetal acidemia, not as a cause of NR4A2-related syndrome. The findings relate to pregnancy complications rather than the genetic condition affecting the child.

  • NR4A2 mRNA levels in maternal blood correlate with severe placental insufficiency.
  • The study focuses on fetal growth restriction and stillbirth risk, not NR4A2 syndrome.
  • NR4A2 acts here as a biomarker for placental health, not a disease gene.
  • No clinical implications exist for managing NR4A2-related syndromes in children.
low2020-05-20 · Aging

LncRNA H19 diminishes dopaminergic neuron loss by mediating microRNA-301b-3p in Parkinson's disease via the HPRT1-mediated Wnt/β-catenin signaling pathway.

Jiang J, Piao X, Hu S, Gao J, Bao M

Overexpressing the long non-coding RNA H19 protects dopaminergic neurons in a mouse model of Parkinson's disease by activating the Wnt/beta-catenin signaling pathway. This protective effect occurs because H19 binds to microRNA-301b-3p, which prevents the suppression of HPRT1 and allows for increased expression of key neuronal genes like Nurr-1.

  • H19 overexpression reduces dopaminergic neuron loss in Parkinson's disease mouse models.
  • The mechanism involves H19 binding to miR-301b-3p to regulate HPRT1 levels.
  • HPRT1 activation triggers the Wnt/beta-catenin pathway to support neuronal survival.
  • Key dopaminergic genes including Nurr-1, Pitx-3, and NeuroD1 increase with this treatment.
low2020-05-20 · Neuropeptides

Dysfunctional Nurr1 promotes high glucose-induced Müller cell activation by up-regulating the NF-κB/NLRP3 inflammasome axis.

Li W, Liu X, Tu Y, Ding D, Yi Q, Sun X, Wang Y, Wang K, Zhu M, Mao J

This study shows that high glucose levels disable Nurr1 in eye cells, triggering inflammation and cell damage in a mouse model of diabetic retinopathy. Treating these mice with a drug that activates Nurr1 reduced nerve cell loss, suggesting this pathway could be a target for eye disease treatment.

  • High glucose disables Nurr1, leading to increased inflammation in retinal Müller cells.
  • Restoring Nurr1 activity protects retinal ganglion cells in diabetic mice.
  • The drug C-DIM12 activates Nurr1 and reduces nerve damage in animal models.
  • This research focuses on eye disease mechanisms, not NR4A2-related movement disorders.
low2020-05-15 · Disease models & mechanisms

The transcription factor Nurr1 is upregulated in amyotrophic lateral sclerosis patients and SOD1-G93A mice.

Valsecchi V, Boido M, Montarolo F, Guglielmotto M, Perga S, Martire S, Cutrupi S, Iannello A, Gionchiglia N, Signorino E, Calvo A, Fuda G, Chiò A, Bertolotto A, Vercelli A

This study finds that the protein Nurr1 increases in the blood of ALS patients and in the spinal cords of ALS mice, where it acts to reduce inflammation. The research suggests Nurr1 is part of the body's early protective response against neurodegeneration, although this natural mechanism is not strong enough to stop the disease.

  • Nurr1 levels rise in the blood of human ALS patients.
  • Nurr1 increases in spinal cords of ALS mice during early disease stages.
  • Nurr1 reduces inflammation by suppressing pro-inflammatory targets in mouse models.
  • Nurr1 promotes protective factors but cannot reverse ALS progression alone.
low2020-05-12 · Frontiers in molecular neuroscience

α-Synuclein Negatively Regulates Nurr1 Expression Through NF-κB-Related Mechanism.

Jia C, Qi H, Cheng C, Wu X, Yang Z, Cai H, Chen S, Le W

This study shows that alpha-synuclein reduces Nurr1 levels in dopamine neurons by interfering with the NF-kappa B signaling pathway. This mechanism explains how pathological protein accumulation might contribute to the loss of dopamine cells seen in Parkinson's disease.

  • Alpha-synuclein lowers Nurr1 expression and its downstream gene activity.
  • The reduction occurs via transcriptional inhibition, not mRNA stability changes.
  • Alpha-synuclein suppresses NF-kappa B, which normally activates the Nurr1 promoter.
  • This pathway links protein aggregation to dopamine neuron vulnerability in Parkinson's.
low2020-05-09 · Aging and disease

The Critical Role of Nurr1 as a Mediator and Therapeutic Target in Alzheimer's Disease-related Pathogenesis.

Jeon SG, Yoo A, Chun DW, Hong SB, Chung H, Kim JI, Moon M

This review discusses how the Nurr1 protein influences Alzheimer's disease mechanisms, such as inflammation and neuronal survival, rather than focusing on its role in NR4A2-related neurodevelopmental disorders. It suggests that targeting Nurr1 could potentially treat Alzheimer's or similar neurodegenerative conditions. The paper does not provide evidence relevant to the specific genetic syndrome affecting your child.

  • The paper is a review of Nurr1's role in Alzheimer's disease pathogenesis.
  • It highlights Nurr1's function in regulating inflammation and neuronal survival.
  • The authors propose Nurr1 as a potential therapeutic target for neurodegeneration.
  • The study does not address NR4A2 mutations or childhood developmental phenotypes.
  • No clinical data or human trials related to NR4A2 syndromes are included.
low2020-05-06 · The Journal of comparative neurology

In search of common developmental and evolutionary origin of the claustrum and subplate.

Bruguier H, Suarez R, Manger P, Hoerder-Suabedissen A, Shelton AM, Oliver DK, Packer AM, Ferran JL, García-Moreno F, Puelles L, Molnár Z

This study compares the developmental origins and gene expression of the claustrum and subplate in rodents and primates to propose a shared evolutionary history. It uses Nurr1/Nr4a2 as one of many markers to support this anatomical theory but does not investigate NR4A2-related syndromes or potential treatments.

  • The paper compares claustrum and subplate development across species using multiple biological markers.
  • Nurr1/Nr4a2 expression is cited as evidence for a common evolutionary origin of these brain regions.
  • The research focuses on comparative neurology and evolution, not human disease or therapy.
  • No clinical data, patient cohorts, or treatment strategies for NR4A2 syndromes are presented.
low2020-05-01 · Endocrinology

The Transcription Factor NR4A2 Plays an Essential Role in Driving Prolactin Expression in Female Pituitary Lactotropes.

Peel MT, Ho Y, Liebhaber SA

This study shows that the NR4A2 protein helps control prolactin production in mouse pituitary cells. It does not address brain development, dopamine pathways, or symptoms relevant to NR4A2-related syndromes.

  • NR4A2 enhances prolactin expression in mouse lactotrope cells.
  • The study uses conditional gene inactivation in mice.
  • No findings relate to human neurodevelopment or dopamine function.
low2020-04-29 · Genes

Genetic and Epigenetic Modification of Rat Liver Progenitor Cells via HNF4α Transduction and 5' Azacytidine Treatment: An Integrated miRNA and mRNA Expression Profile Analysis.

Bolleyn J, Rombaut M, Nair N, Branson S, Heymans A, Chuah M, VandenDriessche T, Rogiers V, De Kock J, Vanhaecke T

This study examines liver progenitor cells in rats and finds that NR4A2 appears only as an incidental molecular target within a computational prediction of cell viability changes. The research focuses on hepatic differentiation and epigenetic modification, with no connection to the nervous system or human clinical outcomes.

  • The study uses rat liver cells, not human neurons or brain tissue.
  • NR4A2 is identified only as a predicted target of microRNA regulation.
  • No experiments involve NR4A2 function, mutation, or therapeutic intervention.
  • Findings relate to liver cell maturation and apoptosis pathways.